A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated

Clinical trial NCT04716114 · UNKNOWN

Trial details

NCT number: NCT04716114
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Acute Myeloid Leukemia (AML)

Start date: 2021-03-24
Primary completion: 2025-12-01
Enrollment: 315

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.